I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

62.4 million Indians were reported to have type 2 diabetes mellitus (T2DM) putting India on the forefront of diabetic epidemic across globe.\[[@ref1][@ref2]\] Fear of hypoglycaemia and gain in body weight act as barriers for initiation of insulin therapy.\[[@ref3]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref4]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref5]\] This short communication presents the results for patients enrolled from Andhra Pradesh, India.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 3077 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (79.7%) started on or switched to biphasic insulin aspart. Other groups were insulin detemir (*n* = 308), insulin aspart (*n* = 226), basal insulin plus insulin aspart (*n* = 21) and other insulin combinations (*n* = 68).

###### 

Overall demographic data

![](IJEM-17-542-g001)

After 24 weeks of treatment, overall hypoglycaemic events reduced in both insulin naïve (from 0.9 events/patient-year to 0.0 events/patient-year) and insulin user (from 0.6 events/patient-year to 0.0 events/patient-year) groups. No hypoglycaemic episode in insulin naive group even at 24 weeks suggests low event rate than insulin users at baseline. A decrease in body weight was also observed at the end of the study. SADRs including major hypoglycaemic events did not occur in any of the study patients. Blood pressure decreased while overall lipid profile and quality of life improved at week 24 in the total cohort \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data
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###### 

Insulin dose

![](IJEM-17-542-g003)

All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data

![](IJEM-17-542-g004)

Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 2452 patients started on biphasic insulin aspart ± OGLD, of which 1939 (79.1%) were insulin naïve and 513 (20.9%) were insulin users. After 24 weeks of starting or switching to biphasic insulin aspart, hypoglycaemia reduced to nil for both insulin naïve (0.9 events/patient-year at baseline) and insulin user (0.7 events/patient-year at baseline) groups. Body weight decreased and quality of life improved after 24 weeks \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-542-g005)

###### 

Insulin dose

![](IJEM-17-542-g006)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-542-g007)

Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 21 patients started on basal + insulin aspart ± OGLD, of which 11 (52.4%) were insulin naïve and 10 (47.6%) were insulin users. After 24 weeks of starting or switching to insulin aspart, hypoglycaemic events reduced from 1.2 events/patient-year to zero events in insulin naive group, whereas hypoglycaemia was nil in insulin user group similar to baseline. A decrease in body weight and improvement in quality of life was also observed at 24 weeks \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-542-g008)

###### 

Insulin dose

![](IJEM-17-542-g009)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-542-g010)

Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 308 patients who started on insulin detemir ± OGLD, of which 250 (81.2%) were insulin naïve and 58 (18.8%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemic events reduced to nil for both insulin naïve (0.8 events/patient-year at baseline) and insulin user (0.2 events/patient-year at baseline) groups. Body weight decreased and quality of life improved after 24 weeks of treatment \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data

![](IJEM-17-542-g011)

###### 

Insulin dose

![](IJEM-17-542-g012)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for both insulin-naïve and insulin user groups \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data

![](IJEM-17-542-g013)

Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 226 patients started on insulin aspart ± OGLD, of which 129 (57.1%) were insulin naïve and 97 (42.9%) were insulin users. After 24 weeks of treatment starting or switching to insulin aspart hypoglycaemia reduced to zero for both insulin naïve (1.1 events/patient-year at baseline) and insulin user (insulin users: 0.4 events/patient-year at baseline) groups. A decrease in body weight and improvement in quality of life was observed at 24 weeks \[Tables [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose

![](IJEM-17-542-g015)

All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for both insulin naïve and insulin user groups \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-542-g016)

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues (biphasic insulin aspart; basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients after 24 week of treatment. A decrease in body weight was observed for all the four regimens. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in Andhra Pradesh, India.
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